Onco Actu du 18 mai 2018

	1. Biologie
How pancreatic cancer spreads after surgery [Cold Spring Harbor Lab] The 2-week period following surgical removal of pancreatic tumors offers a window during which efforts might be made to keep cortisol levels down and T cells strong so the patient’s own immune system can kill cancer cells that have already made their way to other parts of the body.
	3.1.1 Prévention - Tabac - e-cigs
FDA requires additional e-cigarette makers to provide critical information so the agency can better examine youth use and product appeal, amid continued concerns around youth access to products [FDA] Letters to four companies follow initial request to JUUL Labs as part of an ongoing effort to address youth use under the agency’s Youth Tobacco Prevention Plan.
	4. Dépistage, diagnostic et pronostic
Breath test breakthrough for early diagnosis of oesophageal and gastric cancer [Imperial College] Scientists hope that this test, published in JAMA Oncology today, can be used to help clinicians decide whether patients need further investigations.
	4.10 Dép., diag. & prono. - Poumon
A cancer screening flop: Few smokers seek free lung scans [AP] Lung cancer screening has proved to be stunningly unpopular. Five years after government and private insurers started paying for it, less than 2 percent of eligible current and former smokers have sought the free scans, researchers report.
	4.3 Dép., diag. & prono. - Industriels
OncoNano, Maker of Tumor Imaging Technology, Raises $11.7 Million [Xconomy] OncoNano’s lead product, ONM-100, is an injectable imaging agent that targets the acidic pH within tumors to better distinguish cancer cells from healthy ones during surgery.
	4.9 Dép., diag. & prono. - Sein
Turning 40? You might want to skip this mammography primer from U.S. News [HealthNewsReview] While she’s won fame for treating Angelina Jolie and Sheryl Crow, Funk doesn’t exactly come across as a stickler for evidence-based practices.
	5.10 Traitements - Essais
NIH: 'If we don't report our results we will repeat mistakes' [Outsourcing Pharma] Regulatory agencies are doubling down on compliance – and withholding funds – as the clinical research industry enters an era of accountability and transparency, say NIH officials.
	5.3 Traitements - FDA, EMA, NICE...
Background Analysis: US FDA Advisory Committee to Review Molecular Targets for Pediatric Cancers and Discuss Approaches to Pediatric Drug Development – JUN 20, 2018 (ODAC) [SAC Tracker] Along with discussing the scientific relevance of the proposed targets, the Committee will be asked to consider the timing and need for pediatric evaluations in the context of similar in-class agents and the need for global collaboration.
Who’s delaying generic competition? FDA publishes a long list of drugmakers they say gamed the system [EndPoints] We might see how effective the strategy is when the list gets updated in half a year.
EMA Adopts ICH Q&A on Nonclinical Evaluation for Cancer Drugs [RAPS] The 17-page document includes 41 questions and answers offering additional clarity on ICH S9, including information on studies to support nonclinical evaluations such as toxicology studies and nonclinical data to support trial design and marketing.
FDA calls out 39 drug companies for allegedly blocking access to generics [STAT] “We’re taking these steps today because we believe greater transparency will help reduce unnecessary hurdles to generic drug development and approval,” Gottlieb said.
How A Drugmaker Gamed The System To Keep Generic Competition Away [NPR] Revlimid brought in $8.1 billion — or 63 percent — of Celgene's revenue in 2017. Those numbers are remarkable because both Revlimid and Thalomid are derived from a decades-old drug, thalidomide, that was once sold over the counter in Europe before it was pulled from the market.
F.D.A. Names and Shames Drug Makers to Encourage Generic Competition [NY Times] Celgene, which makes drugs to treat cancer and immune-inflammatory diseases, was named as the subject of 31 inquiries from companies seeking access to Revlimid (lenalidomide), its treatment for multiple myeloma and related diseases; Pomalyst (pomalidomide); and Thalomid (thalidomide).
	5.5.1 ASCO (général)
ASCO 2018: Some pearls from the abstracts [David Sampson] I combed through the abstracts to find some of interest for those of us who are interested less in investing, and more in epidemiology, public health, disparities, quality of care, etc.
	5.5.1.1 ASCO (général) - Industriels
Seattle Genetics Announces Data Presentations at 2018 ASCO Annual Meeting [Seattle Genetics] Of note, an oral presentation will feature updated data from a phase 1 study of enfortumab vedotin for patients with metastatic urothelial cancer.
Bayer highlights latest oncology research at ASCO 2018 [Bayer] Clinical research to be presented from Bayer’s growing oncology portfolio, including radium-223 dichloride, sorafenib, regorafenib, copanlisib and other pipeline compounds.
Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer [Novartis] Results from the Kisqali® MONALEESA clinical trial program, the largest industry- sponsored Phase III registration program researching a CDK4/6 inhibitor in HR+/HER2- advanced breast cancer, will be presented at ASCO.
Takeda to Highlight Broad Oncology Portfolio and Pipeline Data at the American Society of Clinical Oncology (ASCO) and the Congress of the European Hematology Association (EHA) Annual Meetings [Takeda] At ASCO, we will present updated Phase 2 ALTA trial results examining long-term efficacy and safety of ALUNBRIG in patients with ALK+ non-small cell lung cancer who are refractory to crizotinib.
The top winners and losers on ASCO abstract night: Loxo, Blueprint, Jounce, Merck KGaA and more [EndPoints] As more and more biopharma money has been invested in the oncology field in recent years, ASCO has been attracting a bigger range of entrants, and abstract night will help determine who comes out on top during the melee ahead.
	6. Lutte contre les cancers
My cancer is in remission – does this mean I’m cured ? [The Conversation] As it happens, with many cancers in remission, to have survived five years does mean they are probably cured. But there are differences for different cancer types.
	6.1 Observation
Cancer patients waiting up to 18 months for NHS treatment [The Telegraph] The statistics released following Freedom of Information (FOI) requests show one patient waited 541 days for treatment after being referred urgently with suspected cancer by their GP. Another waited 446 days, against a target to complete treatment within 62 days.
Cancer patient waited 541 days for NHS treatment, report says [The Guardian] The official target requires at least 85% of cancer patients to have their first treatment within 62 days of referral by their GP, but this has not been met for 27 months in a row.
	6.10.1 Politiques (USA)
Right-to-try bill headed for vote puts bigger burden on FDA to protect patients, Gottlieb says [STAT] Gottlieb’s comments, made at FDA headquarters on Thursday, indicate that one of President Trump’s top lieutenants believes Congress is moving forward with a bill that contains less of his agency’s input than an alternative version of the bill.
Trump’s Drug Pricing Speech Breaks Little New Ground, Largely Spares Industry [Health Affairs] If this blueprint represents the administration’s current view and appreciation of the subject, I would not expect significant changes “very soon,” despite the President’s statements.
	6.7 DMP, Big Data & applis
Verily Advisory Board series: Linda Avey discusses health data sharing & ownership [Verily] Attitudes will also change if individuals are able to benefit financially from sharing their data – wealth derived from our personal data is being concentrated in too few hands and companies.
Your Emergency Contact Information Could Be Used in a Medical Study [NY Times] Researchers have begun experimenting with using emergency contacts gathered from medical records to build family trees that can be used to study the heritability of hundreds of different attributes, and possibly advance research into diseases and responses to medications.
Rethinking Academic Data Sharing [Simply Statistics] There are a few points that need some serious consideration before we can have any real sharing of health data and at this point I don’t think there are good answers to the questions raised.
	6.7.1 IA/bioinformatique
Why are AI researchers boycotting a new Nature journal—and shunning others? [Science] AI is now moving toward not just open access, but open review.